AstraZeneca v. ScieGen Pharmaceuticals: BRILINTA Patent Settled in 63 Days
AstraZeneca brought a Hatch-Waxman infringement action against ScieGen Pharmaceuticals in Delaware over US10300065, protecting its blockbuster antiplatelet drug BRILINTA (ticagrelor). The case resolved in just 63 days via a negotiated consent judgment that permanently enjoins ScieGen from commercialising its generic ANDA product.
Swift Hatch-Waxman resolution locks ScieGen out of ticagrelor market
AstraZeneca AB and AstraZeneca Pharmaceuticals LP filed suit on 21 December 2023 in the District of Delaware before Judge Richard G. Andrews, asserting that ScieGen Pharmaceuticals’ Abbreviated New Drug Application No. 218962 — covering generic 90 mg and 60 mg ticagrelor tablets — would infringe US Patent No. 10,300,065. BRILINTA is AstraZeneca’s leading antiplatelet therapy prescribed for acute coronary syndrome, and the patent anchors its commercial exclusivity.
The parties reached a negotiated settlement within 63 days, and on 22 February 2024 the court entered a consent judgment permanently enjoining ScieGen and its affiliates, successors, and assigns from making, using, selling, offering to sell, importing, or distributing the defendant product unless specifically authorised under the settlement agreement. All claims and counterclaims were dismissed with prejudice, with no award of costs or attorneys’ fees to either party.
A 63-day resolution is notably fast for Hatch-Waxman litigation, which typically runs 18–30 months to trial. The speed suggests the parties reached commercial alignment quickly — likely through a negotiated market-entry date or licensing term embedded in the confidential settlement agreement, a common resolution mechanism in ANDA cases. The specific authorised-entry terms remain undisclosed, meaning the true competitive impact on AstraZeneca’s exclusivity period cannot be assessed from the public record alone.
Filing to settlement in 63 days
Case duration — well below the median for ANDA patent litigation in Delaware
Consent judgment: permanent injunction with confidential settlement terms
Consent judgment — court-enforceable, not merely contractual
A consent judgment differs from a private settlement agreement: it is entered by the court and carries the force of a judicial order. The court expressly retained jurisdiction to enforce or supervise compliance. This means AstraZeneca can return to court to enforce the injunction without filing a new lawsuit, giving it a significantly stronger enforcement posture than a contract alone would provide.
Stronger than private settlementInjunction binds ScieGen, affiliates, successors, and assigns
The permanent injunction covers not only ScieGen itself but also any affiliate — defined broadly as entities with more than 50% common ownership or equivalent board control — as well as future successors and assigns. This structural breadth is designed to prevent the generic product from entering the market through a corporate restructuring or asset transfer, a common litigation-avoidance tactic in the generics industry.
Anti-circumvention structureANDA filing triggered automatic 30-month stay — settlement locks in exclusivity
Under Hatch-Waxman, an ANDA filer’s Paragraph IV certification triggers an automatic 30-month litigation stay preventing FDA from granting approval while the case is pending. Resolving via consent judgment before that stay expires is consistent with a negotiated market-entry date — AstraZeneca retains control over when, if ever, ScieGen’s generic may launch, with any permitted entry date set by the confidential settlement agreement.
Market exclusivity preservedNo fees awarded — mutual walk-away on litigation costs
The consent judgment expressly provides that costs, disbursements, and attorneys’ fees are not awarded to any party. In a case of this duration, litigation costs would have been modest relative to the commercial stakes of a blockbuster drug like BRILINTA. The mutual cost walk-away is consistent with a commercially negotiated outcome where both sides prioritised deal terms over cost recovery.
Each party bears own costsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AstraZeneca AB | Company | Multinational pharmaceutical company — holder of US10300065B2 covering BRILINTA (ticagrelor)Search in Eureka ↗ |
| Defendant | ScieGen Pharmaceuticals, Inc. | Company | Generic pharmaceutical manufacturer that filed ANDA No. 218962 for generic ticagrelor tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Alexandra M. Joyce | Attorney | Counsel for AstraZeneca ABSearch in Eureka ↗ |
| Plaintiff counsel | Daniel M. Silver | Attorney | Counsel for AstraZeneca ABSearch in Eureka ↗ |
| Defendant counsel | Patricia Smink Rogowski | Attorney | Counsel for ScieGen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Robert S. Silver | Attorney | Counsel for ScieGen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The consent judgment’s operative language — enjoining ScieGen ‘unless otherwise specifically authorized pursuant to the Settlement Agreement’ — is the critical phrase. It confirms that the injunction is absolute on its face but contains a private contractual carve-out for permitted entry. This structure gives AstraZeneca full judicial enforcement rights while preserving the commercial flexibility of a negotiated launch date. The dismissal of all claims and counterclaims with prejudice means ScieGen cannot relitigate validity or non-infringement of US10300065 in a future action arising from the same ANDA.
US10300065B2 — BRILINTA (ticagrelor) antiplatelet formulation patent
US Patent No. 10,300,065 (application number 15/546,626) is assigned to AstraZeneca and protects formulation and/or composition aspects of ticagrelor, the active ingredient in BRILINTA — a P2Y12 receptor antagonist used to reduce cardiovascular events in patients with acute coronary syndrome. The patent’s coverage of 90 mg and 60 mg dosage strengths is commercially significant, as both strengths are indicated for distinct patient populations and represent the full marketed BRILINTA portfolio.
BRILINTA has been one of AstraZeneca’s highest-revenue cardiovascular products, making US10300065 a high-value enforcement asset. Any generic manufacturer seeking to compete with BRILINTA before this patent expires must either design around its claims, mount an invalidity challenge, or negotiate a settlement — as ScieGen did here. The breadth of the injunction, extending to affiliates and successors, suggests AstraZeneca views this patent as a core exclusivity pillar warranting maximum enforcement reach.
Should your ticagrelor product require an FTO analysis against US10300065?
Any company developing, manufacturing, or commercialising ticagrelor formulations — including generic tablet manufacturers, contract development and manufacturing organisations, or in-licensing partners — should treat US10300065 as a mandatory FTO checkpoint. This case confirms AstraZeneca actively enforces this patent against ANDA filers and secures court-backed injunctions swiftly. Assuming the patent is narrow or easily designed around without a formal claim analysis is a commercially dangerous position.
PatSnap Eureka’s FTO Search Agent allows R&D and IP teams to map their ticagrelor formulation against the claims of US10300065B2, identify relevant prior art that may support an invalidity argument, and monitor AstraZeneca’s related continuation filings for new claim activity. Claim monitoring is particularly important here: if AstraZeneca is prosecuting continuations off the same application family, new granted claims could create additional clearance obligations that do not yet appear in a standard FTO.
Run a freedom-to-operate analysis on US10300065B2 to assess your product’s exposure
Run FTO in Eureka →Related ANDA patent cases involving antiplatelet and cardiovascular drug formulations
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the ANDA and antiplatelet drug IP landscape
AstraZeneca’s rapid, injunction-backed resolution of this ANDA challenge signals a disciplined enforcement posture around BRILINTA’s remaining patent life.
Early consent judgments are AstraZeneca’s preferred ANDA defence tool
Resolving in 63 days with a court-ordered injunction — rather than litigating to a merits decision — allows AstraZeneca to secure enforceable market exclusivity while avoiding the risk of an adverse validity finding on US10300065. Competitors and ANDA filers should expect similarly swift, injunction-focused resolutions against other generic challengers.
The confidential settlement likely contains a negotiated launch date
In ANDA consent judgments, ‘unless specifically authorised pursuant to the Settlement Agreement’ language almost invariably signals a negotiated launch date — a date after which ScieGen may enter the market. The commercial exclusivity AstraZeneca actually retains depends entirely on that undisclosed date, which is unobservable from the public record but critical to competitive forecasting.
AstraZeneca v ScieGen — key questions answered
The case was resolved via a consent judgment entered on 22 February 2024, permanently enjoining ScieGen Pharmaceuticals from making, selling, or importing its generic ticagrelor product (ANDA No. 218962). All claims were dismissed with prejudice. The case lasted 63 days from filing.
AstraZeneca asserted US Patent No. 10,300,065 (US10300065B2, application 15/546,626) against ScieGen’s ANDA No. 218962, which covered generic 90 mg and 60 mg versions of BRILINTA (ticagrelor). The consent judgment enjoins ScieGen from infringing this patent through its generic product.
This phrase signals that the confidential settlement agreement contains a negotiated market-entry date or licence — a standard Hatch-Waxman resolution mechanism. The injunction is absolute unless the private settlement permits entry. The specific authorised-entry terms are not disclosed in the public court record.
No. The consent judgment expressly states that costs, disbursements, and attorneys’ fees are dismissed without award to any party. Each party bears its own litigation costs. This is consistent with a commercially negotiated resolution where deal terms were the priority.
The 63-day resolution is significantly faster than the typical 18–30 month timeline for Hatch-Waxman cases litigated to trial. The speed suggests early commercial alignment — likely a negotiated generic launch date embedded in the confidential settlement — rather than a merits-based dispute about patent validity or infringement.
PatSnap Eureka searches patents and litigation data to answer instantly.